Zacks Research Upgrades Gyre Therapeutics (NASDAQ:GYRE) to Hold

Gyre Therapeutics (NASDAQ:GYRE) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings downgraded shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Down 3.4%

GYRE opened at $7.01 on Monday. Gyre Therapeutics has a 52 week low of $5.44 and a 52 week high of $9.42. The stock has a market cap of $781.54 million, a PE ratio of -77.88 and a beta of 1.89. The business has a 50 day moving average of $6.52 and a 200-day moving average of $7.25.

Insider Buying and Selling

In related news, CEO Ying Luo sold 10,136 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. This represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. This trade represents a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 32,535 shares of company stock worth $219,580. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

Several large investors have recently modified their holdings of GYRE. Bank of America Corp DE grew its position in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Gyre Therapeutics in the fourth quarter worth approximately $77,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after buying an additional 7,361 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.